Pharma Technology Focus - Issue 10

In this issue we explore the best strategies and technology that can help to make clinical trials quicker, safer and more cost-efficient.


Read the latest issue of Pharma Technology Focus

The management of clinical trials is a long and costly process, involving many parties providing and requiring information at different times. In the latest issue we explore current trends and issues surrounding clinical trials and speak to industry insiders about their best practices and strategies for successful trials.

We investigate how the advent of cloud computing can improve the efficiency and security of studies and find out how imaging biomarkers could help to speed up the process of getting new drugs to patients. We also ask experts about the best strategies for choosing partner organisations and for selecting trial sites, find out how rare disease trials are dodging R&D budget cuts, and shed light on the delicate balance between public demand for transparency in the publication of trial results and the need for commercial confidentiality.

To read this issue for free, click here.

In this issue

Ahead in the Cloud
As the volume and complexity of clinical trial data grows, scientists need new ways to filter information. We ask insiders why moving to the cloud could reduce clinical trial costs, and accelerate innovation.
Read the full article.

Need for Speed
If used properly, imaging biomarkers could hold the key to faster, more cost-effective drug development. we find out more about this predictive imaging technology and how it could help speed up the process of getting vital new drugs to patients.
Read the full article.

Trial and Error
Site selection is often an underrated process, one that is essential for a successful clinical trial. We ask the experts about the right strategies for selecting sites capable of meeting equipment, staff and trial patient requirements.
Read the full article.

Less is More
While one may expect that widespread R&D budget cuts would lead to an increased focus on drugs with the potential to produce the greatest revenues while pushing aside molecules that only affect small populations, the favoured strategy is in fact quite the opposite. We find out why clinical trials for rare diseases should not be affected by the sector's ever-decreasing budget.
Read the full article.

Road to Success
Identifying and selecting the right investigator has a significant impact on the outcome of a clinical trial. Wendy Verret of Apt Pharmaceuticals tells us about the delicate process of investigator selection, and unveils some best practices for a successful clinical outcome from a sponsor's point of view.
Read the full article.

Publish and Be Damned
As the pharmaceutical industry faces growing public demand for greater transparency in the publication of drug trial results, we ask Christine-Lise Julou of the EFPIA about the risks of misinterpretation and the need to respect commercial confidentiality.
Read the full article.

Next Issue: Manufacturing and Ingredients

As manufacturing models evolve to embrace quality by design and process analytical technology, companies are reassessing the way they produce drugs. Next month we look at the latest developments in the sector. We explore the concept of continuous manufacturing and profile technologies in the research pipeline that could revolutionise operations.

Active pharmaceutical ingredients, of course, are vital to the manufacturing process. We look at efforts to monitor and certify the quality of APIs, such as the World Health Organization's Prequalification of Medicines Programme, and find out how API contract manufacturers can stay ahead of the game in an increasingly competitive market.

Digital Magazine FAQ

The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.

Read the latest issue here.

View the archive of past issues.